Related Experiment Video
Updated: Mar 18, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators
Madelyn Schmidt1, Travis S Dowdle2, Georgiy Golovko3
1School of Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
Abstract:
Background: Psoriatic arthritis (PsA) is a rapidly progressive arthritis that is difficult to prevent and treat. The comparative risk of PsA development in psoriasis patients prescribed PsA-approved immunomodulators is unknown. Methods: We assessed the 3-year risk of PsA in psoriasis patients on immunomodulators of IL-12, 17, 23, tumor necrosis factor alpha, JAK1, and JAK3. Using the TriNetX Research Network, we identified patients with psoriasis and the use of an immunomodulatory agent. The immunomodulatory agents assessed included adalimumab, infliximab, ixekizumab, secukinumab, tildrakizumab, certolizumab pegol, risankizumab, etanercept, guselkumab, and ustekinumab. Results: Overall, IL-23 inhibitors risankizumab, guselkumab, and ustekinumab had the greatest decreased risk of PsA. Conclusion: Physicians can consider risankizumab, guselkumab, and ustekinumab as treatment options for psoriasis patients with PsA risk factors to mitigate disease progression and improve patients' quality of life.
More Related Videos
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Relative Risk
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

